Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine.
Evidence of early changes in neural plasticity may aid the prediction of rapid-onset antidepressant drugs. Here we compared the dual α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, to the SNRI, venlafaxine, with regards to their effect on rat brain expression of a pa...
Main Authors: | Serres, F, Millan, M, Sharp, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)
by: Junko Takata, et al.
Published: (2019-08-01) -
Differences between SSRI and SNRI in depression treatment
by: Mateusz Grego, et al.
Published: (2025-01-01) -
Use of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and Sweden.
by: Helga Zoega, et al.
Published: (2015-01-01) -
Plasma concentrations of SSRI/SNRI after bariatric surgery and the effects on depressive symptoms
by: Patrick Pasi, et al.
Published: (2023-04-01) -
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
by: Philippe Courtet
Published: (2010-08-01)